Non-small cell lung cancer recurrent – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Wed, 24 Jun 2026 04:15:47 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Non-small cell lung cancer recurrent – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study testing BNT326 and BNT327 with drug combination for safety and effectiveness in people with advanced non-small cell lung cancer https://clinicaltrials.eu/trial/a-study-testing-bnt326-and-bnt327-with-drug-combination-for-safety-and-effectiveness-in-people-with-advanced-non-small-cell-lung-cancer/ Wed, 29 Apr 2026 15:08:44 +0000 https://clinicaltrials.eu/trial/a-study-testing-bnt326-and-bnt327-with-drug-combination-for-safety-and-effectiveness-in-people-with-advanced-non-small-cell-lung-cancer/ This study examines non-small cell lung cancer, which is an advanced form of lung cancer. The study will test different combinations of investigational medications. These include BNT326 and BNT327, which are experimental drugs given through infusion into a vein. Some participants may also receive standard cancer medications such as paclitaxel, carboplatin, pemetrexed, or pembrolizumab, depending on which part of the study they are in. The purpose of this study is to determine the appropriate dose of BNT326 when combined with BNT327, to assess how safe these medications are when used together, and to evaluate whether this combination treatment may help control the cancer.

The study is divided into different parts. The first part will test different dose levels of the investigational medications to find the most suitable dose for further testing. During this phase, doctors will carefully monitor participants for any side effects. The following parts of the study will test the chosen dose in larger groups of people with advanced non-small cell lung cancer to better understand how well the treatment works and how safe it is. Throughout the study, participants will receive the medications through infusion into a vein. Doctors will regularly check how the cancer responds to treatment using imaging scans and other assessments.

During the study, participants will need to provide a tissue sample from their tumor, either from a previously stored sample or from a new biopsy if needed. The study will track various aspects of participant health and treatment response, including any side effects that occur, whether the cancer shrinks or stops growing, and how long any positive effects last. Blood samples will be collected at different times to measure the levels of the investigational medications in the body and to check whether the immune system develops a response to these medications.

]]> A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment https://clinicaltrials.eu/trial/a-study-of-bms-986504-with-drug-combination-compared-to-placebo-with-drug-combination-in-patients-with-advanced-non-small-cell-lung-cancer-starting-first-treatment/ Wed, 29 Apr 2026 15:07:43 +0000 https://clinicaltrials.eu/trial/a-study-of-bms-986504-with-drug-combination-compared-to-placebo-with-drug-combination-in-patients-with-advanced-non-small-cell-lung-cancer-starting-first-treatment/ This study is looking at metastatic non-small cell lung cancer, which is a type of lung cancer that has spread to other parts of the body. The study is specifically for people whose cancer has a particular genetic change called homozygous MTAP deletion, which means a specific gene is missing from both copies of the chromosome in the cancer cells. The treatments being tested include BMS-986504, which is an experimental medicine given as a tablet by mouth, along with pembrolizumab, which is a medicine given through a vein that helps the immune system fight cancer. The study also includes chemotherapy medicines that are given through a vein, such as paclitaxel, paclitaxel albumin-bound, carboplatin, cisplatin, and pemetrexed. Some participants will receive a placebo instead of BMS-986504, which is an inactive substance that looks like the real medicine but contains no active ingredient.

The purpose of the study is to find out if adding BMS-986504 to pembrolizumab and chemotherapy can help people with this type of lung cancer live longer without their cancer getting worse, and to see if it can help them live longer overall, compared to treatment with placebo plus pembrolizumab and chemotherapy. The study will also look at how well the cancer responds to treatment and how long any response lasts, as well as checking for any unwanted effects that the treatments may cause.

The study will be conducted in two phases. Participants will be randomly assigned to receive either BMS-986504 or placebo, both given together with pembrolizumab and chemotherapy. The specific chemotherapy medicines used will depend on the type of lung cancer each person has. Throughout the study, doctors will perform regular check-ups and scans to see how the cancer is responding to treatment and to monitor for any side effects. Treatment will continue for as long as it is helping and not causing unacceptable side effects.

]]> Study of subcutaneous nivolumab with ipilimumab and chemotherapy in previously untreated patients with metastatic or recurrent non-small cell lung cancer https://clinicaltrials.eu/trial/study-of-subcutaneous-nivolumab-with-ipilimumab-and-chemotherapy-in-previously-untreated-patients-with-metastatic-or-recurrent-non-small-cell-lung-cancer/ Wed, 29 Apr 2026 15:07:07 +0000 https://clinicaltrials.eu/trial/study-of-subcutaneous-nivolumab-with-ipilimumab-and-chemotherapy-in-previously-untreated-patients-with-metastatic-or-recurrent-non-small-cell-lung-cancer/ This study focuses on treating Non-small cell lung cancer (NSCLC) that has spread to other parts of the body or has come back after previous treatment. The study will test a combination of different medications: nivolumab (given as an injection under the skin), ipilimumab (given through a vein), and chemotherapy drugs including pemetrexed, cisplatin, carboplatin, and paclitaxel.

The main purpose of this research is to understand how the body processes nivolumab when it is given under the skin in two different doses, along with ipilimumab and chemotherapy. The study will look at how the medications work together and how they are processed by the body.

During the study, participants will receive nivolumab as an injection under the skin, while ipilimumab and chemotherapy medications will be given through a vein. The treatment will continue for up to 24 months. Throughout the study, doctors will monitor how participants respond to the treatment and check for any side effects that may occur.

]]> Study Comparing Nivolumab and Relatlimab with Chemotherapy to Pembrolizumab with Chemotherapy for Advanced Non-Small Cell Lung Cancer Patients https://clinicaltrials.eu/trial/study-comparing-nivolumab-and-relatlimab-with-chemotherapy-to-pembrolizumab-with-chemotherapy-for-advanced-non-small-cell-lung-cancer-patients/ Wed, 29 Apr 2026 15:05:45 +0000 https://clinicaltrials.eu/trial/study-comparing-nivolumab-and-relatlimab-with-chemotherapy-to-pembrolizumab-with-chemotherapy-for-advanced-non-small-cell-lung-cancer-patients/ This clinical trial is focused on studying a type of lung cancer known as non-small cell lung cancer (NSCLC), specifically in its advanced stages, either stage IV or when it has returned after treatment. The study aims to compare two different treatment approaches to see which one helps patients live longer. One group of participants will receive a combination of two medications, nivolumab and relatlimab, along with chemotherapy. The other group will receive pembrolizumab with chemotherapy. These treatments are given through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein.

The main goal of the study is to determine if the combination of nivolumab and relatlimab with chemotherapy is more effective in extending the lives of patients compared to pembrolizumab with chemotherapy. The study will also look at other factors, such as how long the cancer stays under control and the overall response to the treatments. Participants will be monitored for any side effects from the medications.

The study will take place over several years, with the estimated completion date in 2027. Participants will be randomly assigned to one of the two treatment groups and will receive their assigned treatment as part of the study. The results will help determine the best first-line treatment option for people with this type of lung cancer.

]]> Study on Osimertinib and Savolitinib for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer After Previous Osimertinib Treatment https://clinicaltrials.eu/trial/study-on-osimertinib-and-savolitinib-for-patients-with-advanced-or-metastatic-non-small-cell-lung-cancer-after-previous-osimertinib-treatment/ Wed, 29 Apr 2026 15:01:28 +0000 https://clinicaltrials.eu/trial/study-on-osimertinib-and-savolitinib-for-patients-with-advanced-or-metastatic-non-small-cell-lung-cancer-after-previous-osimertinib-treatment/ This clinical trial is focused on studying a type of lung cancer known as non-small cell lung cancer (NSCLC) that is locally advanced or has spread to other parts of the body. The study is specifically looking at patients whose cancer has certain genetic changes, called EGFR mutations and MET amplifications. These changes can affect how the cancer grows and responds to treatment. The trial is testing a combination of two medications: osimertinib and savolitinib. Osimertinib is already used to treat this type of lung cancer, and the study aims to see if adding savolitinib can help patients who have not responded well to osimertinib alone.

The purpose of the study is to determine how effective the combination of osimertinib and savolitinib is in treating this specific type of lung cancer. Participants in the study will take these medications in the form of film-coated tablets, which are taken by mouth. The study will monitor how the cancer responds to the treatment over time, as well as any changes in the size of the tumors. The trial will also collect information on the safety of the treatment and any side effects that may occur.

Throughout the study, participants will undergo regular check-ups and tests to assess their health and the progress of their cancer. These tests may include imaging scans like MRI or CT scans to measure the size of the tumors. The study will also track the levels of the medications in the blood to understand how they are processed by the body. The trial is expected to continue until May 2025, with the goal of providing valuable information on the potential benefits of combining osimertinib and savolitinib for patients with this type of lung cancer.

]]> Study on the Safety and Effectiveness of Azacitidine and Pembrolizumab for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer After Platinum Treatment https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-azacitidine-and-pembrolizumab-for-patients-with-advanced-or-metastatic-non-small-cell-lung-cancer-after-platinum-treatment/ Wed, 29 Apr 2026 15:01:02 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-azacitidine-and-pembrolizumab-for-patients-with-advanced-or-metastatic-non-small-cell-lung-cancer-after-platinum-treatment/ This clinical trial is focused on studying a type of lung cancer known as non-small cell lung cancer (NSCLC), which is locally advanced or has spread to other parts of the body. The study is designed for patients who have already received a specific type of chemotherapy called platinum-based treatment. The trial aims to evaluate the safety and effectiveness of a combination of two treatments: CC-486 (also known as oral azacitidine) and pembrolizumab, which is also referred to by its code name, MK-3475. Pembrolizumab is a medication that is given through an injection into a vein, while azacitidine is taken as a tablet by mouth.

The purpose of the study is to compare the effects of the combination of CC-486 and pembrolizumab against pembrolizumab with a placebo in patients with NSCLC. Participants in the study will be randomly assigned to receive either the combination treatment or pembrolizumab with a placebo. The study will monitor the participants over a period to assess how well the treatments work and to check for any side effects. The trial will help researchers understand if the combination of CC-486 and pembrolizumab can improve outcomes for patients with this type of lung cancer.

Throughout the study, participants will receive regular check-ups and monitoring to ensure their safety and to track the progress of their treatment. The study is expected to continue until 2025, providing valuable information on the potential benefits and risks of using CC-486 in combination with pembrolizumab for treating advanced NSCLC. This research could lead to new treatment options for patients with this challenging form of lung cancer.

]]> Study of CLN-081 tablets in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations who have previously received platinum chemotherapy https://clinicaltrials.eu/trial/study-of-cln-081-for-patients-with-advanced-non-small-cell-lung-cancer-with-egfr-exon-20-mutations-after-chemotherapy/ Wed, 29 Apr 2026 14:59:11 +0000 https://clinicaltrials.eu/trial/study-of-cln-081-for-patients-with-advanced-non-small-cell-lung-cancer-with-egfr-exon-20-mutations-after-chemotherapy/ This clinical trial investigates a treatment for patients with Non-Small Cell Lung Cancer that has a specific genetic change called EGFR Exon 20 insertion mutations. The cancer being studied is either locally advanced or has spread to other parts of the body (metastatic). The study focuses on patients whose cancer has continued to grow after receiving treatment with platinum-based chemotherapy.

The study tests a new medication called CLN-081, which comes in tablet form and is taken by mouth. This is a combined Phase 1 and Phase 2 study that aims to understand how safe the medication is, how the body processes it, and how well it works in treating the cancer. The medication will be given twice daily with food.

During the study, doctors will monitor patients’ response to treatment and track any side effects that may occur. The study includes different groups of patients and will look at how the medication works both with and without food. Patients will undergo regular health checks and imaging scans to assess how their cancer responds to the treatment.

]]> Study of platinum, pemetrexed, atezolizumab and bevacizumab combination in patients with advanced non-small cell lung cancer who have EGFR, ALK or ROS1 mutations and progressed after targeted therapy https://clinicaltrials.eu/trial/study-of-platinum-pemetrexed-and-atezolizumab-for-advanced-non-small-cell-lung-cancer-in-patients-with-egfr-alk-or-ros1-mutations-after-targeted-therapy/ Wed, 29 Apr 2026 14:58:13 +0000 https://clinicaltrials.eu/trial/study-of-platinum-pemetrexed-and-atezolizumab-for-advanced-non-small-cell-lung-cancer-in-patients-with-egfr-alk-or-ros1-mutations-after-targeted-therapy/ This study focuses on patients with non-squamous non-small cell lung cancer (stage IIIB/IV) who have specific genetic changes including EGFR mutations, ALK rearrangement, or ROS1 fusion, and whose disease has progressed after previous targeted treatments. The study will test a combination of several cancer medicines: platinum-based chemotherapy (cisplatin or carboplatin), pemetrexed, atezolizumab, and in some cases, bevacizumab.

The main purpose is to determine how well this combination of medications works in treating the cancer, particularly by measuring how many patients respond to the treatment after 4 cycles. The study will look at two separate groups of patients – one group receiving bevacizumab and another group not receiving it – to better understand the effectiveness of different drug combinations.

During the study, participants will receive the medications through intravenous infusion. The treatment can continue for up to 36 months, depending on how well it works and how well it is tolerated. Throughout the study, patients will have regular check-ups to monitor their response to treatment and any side effects. The study will also track how long patients live without their disease getting worse and measure changes in cancer-related symptoms.

]]> Study Comparing Ensartinib and Crizotinib for Patients with ALK-Positive Non-Small Cell Lung Cancer https://clinicaltrials.eu/trial/study-comparing-ensartinib-and-crizotinib-for-patients-with-alk-positive-non-small-cell-lung-cancer/ Wed, 29 Apr 2026 14:58:10 +0000 https://clinicaltrials.eu/trial/study-comparing-ensartinib-and-crizotinib-for-patients-with-alk-positive-non-small-cell-lung-cancer/ This clinical trial is focused on studying a type of lung cancer known as Non-Small Cell Lung Cancer (NSCLC) that is positive for a specific mutation called Anaplastic Lymphoma Kinase (ALK). The study is comparing two treatments: Ensartinib, also known by its code name X-396, and Crizotinib, which is marketed under the name XALKORI. Both medications are taken orally in capsule form. The purpose of the study is to evaluate how effective and safe these treatments are for patients with this specific type of lung cancer.

Participants in the study will receive either Ensartinib or Crizotinib. The study will monitor the progress of the disease and any side effects experienced by the participants. The trial will last for a period of time, during which participants will have regular check-ups and assessments to track their health and the cancer’s response to the treatment. The study aims to determine which medication is more effective in controlling the cancer and improving the quality of life for patients.

This trial is important for understanding the best treatment options for patients with ALK-positive NSCLC. By comparing these two medications, researchers hope to find the most effective way to manage this type of lung cancer and provide better outcomes for patients. Participants will be closely monitored throughout the study to ensure their safety and to gather valuable information about the treatments being tested.

]]> Study Comparing Ociperlimab and Tislelizumab with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer https://clinicaltrials.eu/trial/study-comparing-ociperlimab-and-tislelizumab-with-pembrolizumab-for-patients-with-advanced-non-small-cell-lung-cancer/ Wed, 29 Apr 2026 14:47:57 +0000 https://clinicaltrials.eu/trial/study-comparing-ociperlimab-and-tislelizumab-with-pembrolizumab-for-patients-with-advanced-non-small-cell-lung-cancer/ This clinical trial is focused on studying treatments for non-small cell lung cancer, a type of lung cancer that is locally advanced, cannot be surgically removed, or has spread to other parts of the body. The study involves three different treatments: Ociperlimab, an anti-TIGIT antibody, used in combination with Tislelizumab, and a comparison with Pembrolizumab, which is followed by a placebo. The purpose of the study is to compare the overall survival of patients receiving these treatments.

Participants in the study will be randomly assigned to one of two groups. One group will receive Ociperlimab in combination with Tislelizumab, while the other group will receive Pembrolizumab followed by a placebo. The treatments are given as infusions, which means they are administered directly into the bloodstream through a vein. The study will monitor the participants over a period of time to assess the effectiveness of the treatments in improving survival rates.

The trial aims to provide valuable information on how these treatments can help patients with non-small cell lung cancer. By comparing the different treatment options, researchers hope to find the most effective approach for managing this type of cancer. The study will also look at the quality of life of participants and any side effects they may experience during the trial.

]]> Study of INCB099280 and Adagrasib for Adults with Advanced Solid Tumors with KRASG12C Mutation https://clinicaltrials.eu/trial/study-of-incb099280-and-adagrasib-for-adults-with-advanced-solid-tumors-with-krasg12c-mutation/ Wed, 29 Apr 2026 14:47:48 +0000 https://clinicaltrials.eu/trial/study-of-incb099280-and-adagrasib-for-adults-with-advanced-solid-tumors-with-krasg12c-mutation-2/ This clinical trial is focused on studying a type of cancer known as Advanced Solid Tumors that have a specific genetic change called the KRASG12C mutation. The study will test a combination of two medications: INCB099280 and Adagrasib. These medications are taken as film-coated tablets by mouth. The purpose of the study is to evaluate how safe and tolerable this combination is for patients with these types of tumors.

Participants in the study will receive the combination of INCB099280 and Adagrasib to see how their bodies respond to the treatment. The study will monitor for any side effects and determine the most suitable dose for patients. The trial will also look at how the medications are processed in the body and their effects on the tumors.

The study is designed to help understand the potential benefits and risks of using these medications together for treating Advanced Solid Tumors with the KRASG12C mutation. Participants will be closely monitored throughout the study to ensure their safety and to gather important information about the treatment’s effectiveness.

]]> Study of Relatlimab and Nivolumab with Chemotherapy for Patients with Stage IV or Recurrent Non-Small Cell Lung Cancer https://clinicaltrials.eu/trial/study-of-relatlimab-and-nivolumab-with-chemotherapy-for-patients-with-stage-iv-or-recurrent-non-small-cell-lung-cancer/ Wed, 29 Apr 2026 14:29:41 +0000 https://clinicaltrials.eu/trial/study-of-relatlimab-and-nivolumab-with-chemotherapy-for-patients-with-stage-iv-or-recurrent-non-small-cell-lung-cancer/ This clinical trial is focused on studying treatments for , which is a type of lung cancer. The study involves two main treatments: and , both of which are given through an intravenous infusion, meaning they are delivered directly into the bloodstream. These treatments are being tested in combination with various chemotherapy drugs, including , , , , and . The purpose of the study is to compare the effectiveness of Relatlimab plus Nivolumab with chemotherapy against Nivolumab with chemotherapy in patients with advanced or recurrent NSCLC.

Participants in the study will receive either the combination of Relatlimab and Nivolumab with chemotherapy or Nivolumab with chemotherapy. The study is designed to be double-blind, meaning neither the participants nor the researchers will know which treatment each participant is receiving. This helps ensure that the results are not biased. The study will take place over a period of time, with regular monitoring to assess the safety and effectiveness of the treatments. Participants will be closely observed for any side effects or changes in their condition.

The study aims to provide valuable information on how these treatments work together and their potential benefits for people with stage IV or recurrent NSCLC. By participating, individuals contribute to research that may improve future treatment options for this type of lung cancer. The trial will help determine if the combination of Relatlimab and Nivolumab with chemotherapy offers a better outcome compared to the current standard treatment of Nivolumab with chemotherapy.

]]> Study on the Safety and Effects of ATL001 and Pembrolizumab in Adults with Advanced Non-Small Cell Lung Cancer https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-atl001-and-pembrolizumab-in-adults-with-advanced-non-small-cell-lung-cancer/ Wed, 29 Apr 2026 14:28:52 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-atl001-and-pembrolizumab-in-adults-with-advanced-non-small-cell-lung-cancer/ This clinical trial is focused on studying a type of lung cancer known as non-small cell lung cancer (NSCLC). The study is exploring a new treatment approach using a personalized therapy called ATL001, which is a type of cell therapy. This therapy is designed to target specific mutations found in cancer cells. The study will also look at how ATL001 works when used alone and in combination with another medication called pembrolizumab, which is already used in cancer treatment.

The main goal of the study is to assess the safety and how well patients tolerate ATL001 as a treatment. Participants in the study will receive the treatment through an infusion, which means the medication is given directly into the bloodstream. The study will monitor patients over time to see how their cancer responds to the treatment and to check for any side effects. The study will also compare the effects of the treatment with those of a placebo.

Throughout the study, patients will have regular check-ups to track their health and the progress of their cancer. The study will measure changes in tumor size and overall health outcomes, such as how long patients live without their cancer getting worse. This research aims to provide new insights into treating non-small cell lung cancer and potentially offer new options for patients with this type of cancer.

]]> Study of INCB099280 for Patients with Advanced Solid Tumors Who Have Not Received Immunotherapy https://clinicaltrials.eu/trial/study-of-incb099280-for-patients-with-advanced-solid-tumors-who-have-not-received-immunotherapy/ Wed, 29 Apr 2026 14:27:04 +0000 https://clinicaltrials.eu/trial/study-of-incb099280-for-patients-with-advanced-solid-tumors-who-have-not-received-immunotherapy/ This clinical trial is focused on studying the effects of a new treatment called INCB099280 on certain types of cancer known as solid tumors. These tumors are advanced or have come back after treatment, and the patients have not previously received a type of treatment called immunotherapy. The purpose of the study is to understand how safe and tolerable the treatment is, and to see how well it works in managing these tumors.

Participants in the study will take INCB099280 in the form of a film-coated tablet. The study will test different doses of the medication, specifically 400 mg, 600 mg, and 800 mg, taken twice a day. The treatment period can last up to 24 weeks. During the study, participants will be monitored for any side effects and changes in their condition. Some participants may receive a placebo, which is a tablet that looks like the treatment but does not contain the active medication.

The study aims to gather information on how the treatment affects the tumors, including whether it can shrink them or stop them from growing. It will also look at how long any positive effects last and how the treatment impacts the overall health and survival of the participants. The results will help determine if INCB099280 could be a useful treatment option for people with these types of cancer in the future.

]]> Study of BMS-986315 and Nivolumab with Chemotherapy for First-line Treatment in Stage IV or Recurrent Non-Small Cell Lung Cancer Patients https://clinicaltrials.eu/trial/study-of-bms-986315-and-nivolumab-with-chemotherapy-for-first-line-treatment-in-stage-iv-or-recurrent-non-small-cell-lung-cancer-patients/ Wed, 29 Apr 2026 14:25:19 +0000 https://clinicaltrials.eu/trial/study-of-bms-986315-and-nivolumab-with-chemotherapy-for-first-line-treatment-in-stage-iv-or-recurrent-non-small-cell-lung-cancer-patients/ This clinical trial is focused on studying treatments for Non-Small Cell Lung Cancer (NSCLC), which is a type of lung cancer. The study involves a new treatment called BMS-986315 and another medication known as Nivolumab. These treatments will be used in combination with chemotherapy, which is a common cancer treatment that uses drugs to kill cancer cells. The chemotherapy drugs involved in this study include Cisplatin, Paclitaxel, Carboplatin, and Pemetrexed Disodium. The purpose of the study is to compare the effectiveness of the combination of BMS-986315 and Nivolumab with chemotherapy against the combination of Nivolumab and chemotherapy alone.

The study will be conducted in two parts. The first part will focus on assessing the safety of the combination of BMS-986315 and Nivolumab with chemotherapy. Safety in this context means checking for any side effects or adverse reactions that participants might experience. The second part will compare how well the treatments work in reducing the size of tumors, which is referred to as the objective response rate. This will help determine if the new combination treatment is more effective than the existing treatment option.

Participants in the study will receive the treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will last for a period of time, with some participants receiving treatment for up to 24 months. The results will be carefully monitored and reviewed by a team of experts to ensure the safety and effectiveness of the treatments being tested. This study aims to provide valuable information that could lead to improved treatment options for people with advanced or recurrent NSCLC.

]]> Study of Taletrectinib for Patients with Advanced or Metastatic ROS1 Positive Non-Small Cell Lung Cancer https://clinicaltrials.eu/trial/study-of-taletrectinib-for-patients-with-advanced-or-metastatic-ros1-positive-non-small-cell-lung-cancer/ Wed, 29 Apr 2026 14:23:16 +0000 https://clinicaltrials.eu/trial/study-of-taletrectinib-for-patients-with-advanced-or-metastatic-ros1-positive-non-small-cell-lung-cancer/ This clinical trial is focused on studying the effects of a medication called Taletrectinib in patients with advanced or metastatic Non-small Cell Lung Cancer (NSCLC) and other solid tumors that are positive for a specific genetic change known as ROS1. The purpose of the study is to evaluate how effective and safe Taletrectinib is for these patients. Taletrectinib is taken orally in the form of a capsule.

The study is designed to observe the response of the cancer to the treatment with Taletrectinib. Patients participating in the study will receive the medication and will be monitored over a period of time to assess how their cancer responds. The study will also look at the safety of the medication, which means checking for any side effects that might occur. Some patients in the study may receive a placebo, which is a substance with no active medication, to compare the effects of Taletrectinib.

Throughout the study, patients will have regular visits to the clinic for check-ups and tests to monitor their health and the progress of their cancer. These visits will help the researchers understand how well Taletrectinib works and how safe it is for patients with ROS1-positive cancers. The study aims to provide valuable information that could lead to better treatment options for patients with these types of cancers in the future.

]]> Study of DS-3939a for Patients with Advanced or Metastatic Solid Tumors https://clinicaltrials.eu/trial/study-of-ds-3939a-for-patients-with-advanced-or-metastatic-solid-tumors/ Wed, 29 Apr 2026 14:23:10 +0000 https://clinicaltrials.eu/trial/study-of-ds-3939a-for-patients-with-advanced-or-metastatic-solid-tumors/ This clinical trial is focused on studying advanced solid tumors, which are types of cancer that have spread beyond their original location and are difficult to treat. The trial will test a new treatment called DS-3939a, which is given as a solution through an intravenous infusion, meaning it is delivered directly into the bloodstream through a vein. The purpose of the study is to evaluate the safety and tolerability of DS-3939a and to see how well it works in treating these advanced cancers.

The study is divided into two parts. In the first part, participants will receive DS-3939a to assess its safety and how well it is tolerated by the body. In the second part, the study will continue to evaluate safety and also measure the treatment’s effectiveness at a recommended dose. This will involve looking at how the cancer responds to the treatment, which is known as the objective response rate. Participants may have different types of advanced cancers, including those of the lung, breast, ovary, and pancreas, among others.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. This includes regular check-ups, laboratory tests, and imaging studies to track the progress of the treatment. The study aims to gather important information that could lead to new treatment options for people with advanced solid tumors. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of DS-3939a.

]]>